Clinical, morphologic, and cytogenetic features were examined in a group of 68 children with myelodysplasia (MDS) referred t o a single institution between 1971-1991. The morphologic French-American-British (FA61 system of classification proved of limited value in this group of patients because 50%
in survival ( P = .00009). The overall 5-year survival for the patients was 31.9% (95% Cl 21.7 t o 44.1) and factors influencing prognosis included: modified FAB type, platelet count, Hb F level, and cytogenetic complexity. We developed a scoring system ("FPC") where each of the following findings at diagnosis scored one point: HbF greater than 1096, platelets 5 4 0 x 109/L, and complex karyotypic changes (two or more clonal structural/numerical abnormalities), which produced groups with highly significant differences, patients with a score of 0 having a 5-year survival of 61.646 (Cl 33% t o 84%). whereas those with a score of t w o or three all died within 4 years of diagnosis. The revised classification and scoring system may prove helpful in making treatment choices in pediatric MDS and now needs t o be tested prospectively in large scale population-based studies. 0 1995 by The American Society of Hematology.
Therefore, we have reviewed all the cases of pediatric MDS seen at this hospital over a 21-year period, producing a more rational classification and devised a scoring system that may be of use in predicting prognosis.
MATERIALS AND METHODS
We reviewed the clinical information and laboratory data on all the patients referred to the Hospital For Sick Children (HSC), Great Ormond Street, during l97 1-1991 in whom a diagnosis of MDS or chronic myeloproliferative disease had been made. The distinction between patients with acute myeloid leukemia (AML) and these diseases can be a fine one, but our patients with AML seen during the same period had been recently reviewed" so we were able to make a systematic attempt to separate the two disorders. We excluded all children who fulfilled the criteria for a primary diagnosis of AML or who had clinical, laboratory, and cytogenetic features of Philadelphia chromosome positive chronic granulocytic leukemia (Ph' positive CGL) and the one patient with therapy-related MDS. We identified a total of 68 patients.
Bone marrow aspirates were reviewed, blind, by three of us, without reference to the clinical findings. Blood films were available from 51 patients (it was not possible to find good quality films for the remainder) and were similarly reviewed;
for all patients the results of full blood count including differential leukocyte count at the time of presentation were available. An attempt was made to classify each patient according to the FAB system' as refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEBT), or chronic myelomonocytic leukemia (CMML). Bone marrow trephine biopsy samples were available for 32 children, and these were reviewed to determine the cellularity and the presence of fibrosis and abnormal location of immature precursor cells (ALIP)."
Cytogenetics. Cells were obtained for analysis from bone marrow samples incubated at 37°C for l to 2 hours or overnight in tissue culture medium containing 10% fetal calf serum. Cultures were harvested and metaphase chromosomes G-banded using standard procedures.I4 Descriptions of karyotypes follow ISCN (1991)."
A cytogenetic complexity score was devised based on the presence or absence of clonal abnormalities and their complexity at the time of diagnosis. Cases with no detectable clonal abnormalities scored 0, a score of one was given to cases having simple abnormalities arising from one event ie. single translocation, other structural abnormality, or gain or loss of one chromosome. A score of two was Abbreviations: BMT, bone marrow transplant (allogeneic); MUD, matched unrelated donor transplant; ABMT, intensive chemotherapy plus autologous bone marrow transplant; NIC, nonintensive chemotherapy (prednisolone 2 6-mercaptopurine).
Still alive.
given to complex abnormalities arising from two or more structural or numerical events. We applied both the original and revised Bournemouth scoring systems'" to assess their value in predicting prognosis in pediatric patients.
We related the FAB classification to the clinical classification for two well described subgroups of pediatric MDS, namely JCML and IMo7.I' Patients were classed as having JCML if they had CMML morphology and raised fetal hemoglobin (HbF) (>IO%). and did not have monosomy 7. Patients with Shwachman's syndrome may have a raised HbF," but did not have morphologic CMML. Monosomy 7 is a common finding in myelodysplasia of both children and adults," but the children classified as having IMo7 in this series were under 4 years of age at presentation with any type of myelodysplasia and monosomy 7. All older children with MDS, who happened to have this cytogenetic finding, were excluded from this definition and classified according to the morphologic (FAB) type.
Standard nonparametric methods were used to analyze the relationship between different characteristics of the study population. Actuarial survival rates were calculated by Kaplan-Meier methods and the differences between survival curves analyzed by the logrank test'* using the Sureal program.
All survivors, except three patients who had been referred from abroad, had been followed until June 1994. The minimum follow-up period was 33 months from the time of diagnosis.
RESULTS
Clinicaljndings. There were 46 males and 22 females, with a median age of 37 months (range, 7 weeks to 11.8 years). The median duration of symptoms before referral was 3 months (range, 0 to 108 months).
Nineteen of the patients had other clinical abnormalities in addition to MDS, and these are shown in Table 1 . Most of the abnormalities associated with MDS have been described previously. Four patients had Shwachman's syndrome. Cases 5 through 7 were members of different families with inherited platelet storage p o o l defects (PSPD). Two of these families had an increased incidence of malignancy; the family tree of case 6, the only child in the series with RARS, is shown in Fig 1, whereas case 7 had a sibling with a brain tumor. Case 8 had neurofibromatosis (NF) in association with CMML (which would be clinically classified as JCML), whereas case 9 had cafe au lait spots, but no other stigmata of NF. There were two pairs of siblings with MDS. Case 10 had multiple congenital abnormalities and CMML, her elder brother had the same diagnoses made before the start of our study period and is excluded. Cases 1 1 and 12 were male twins, both with CMML and a constitutional chromosomal abnormality t(7;16)(pIO;q10); their father also had this translocation, but no hematologic abnormality. The remaining seven cases had a variety of other clinical abnormalities.
There was no discernible association of particular FAB types with any congenital abnormality except for the association of NF with CMML. There were no cases of CMML in the patients with Shwachman's syndrome or PSPD.
Morphology. We were able to assign FAB types on the basis of blood and bone marrow findings to most of the patients. Three children were unclassifiable; all had mild to moderate marrow dysplasia and marked eosinophilia (25% to 42%) in both blood and marrow, and one child had marked skin infiltration. We have classified these children as having eosinophilic MDS; two were female and one male, ages 6, 42, and 99 months, respectively. Two of these cases of MDS with eosinophilia have been published.2'1~"
The largest group of 35 children, 29 males and six females, were classified as CMML and, with a median age at diagnosis of 13 months, (range, 1.7 to 113) were significantly younger than the other groups combined (median 75 months, P = <.00001 by the Mann-Whitney test). Refractory anemia and RAEB were the next most common subtypes ( 1 I and 13, respectively); there were four cases of RAEBT and only one of RARS. There was no particular pattern of age and sex distribution in these groups.
Trephine biopsies from 32 patients were available for review. There was good agreement with the cellularity of the marrow aspirate in the 28 cases in which this comparison could be made. It was possible to examine the trephines for the presence of ALIPS in 26 of the specimens, but there was no correlation with this finding and any FAB subtype. Moderate or marked fibrosis was seen in 2 1 of 26 (8 1 %) of the trephines stained for reticulin.
Cytogenetics. Chromosome data were available from 63 cases, of these, 35 (55%) had clonal abnormalities. Deletion or monosomy of chromosome 7 was the most frequent abnormality; in 17 cases (48% of those with clonal abnormalities) we found whole chromosome loss or, in one case partial loss due to translocation. In addition, the twins with CMML had constitutional 7; 16 translocations, although no acquired changes were found in their marrow cells.
The clones in six cases (17%) contained extra copies of chromosome 8 (in four cases it was the sole abnormality), whereas trisomy 21 and structural abnormalities of chromosome S were each found in four cases (1 1 %). In two of the cases with chromosome 5 involvement the abnormalities were interstitial long-arm deletions, whereas two cases with eosinophilia had translocations involving Sq3 1-33 [t(S; 12) (43 1 ;q13) and t( 1 ;5)(q22;q33)].
Modified classification. We modified the FAB classification by incorporating the categories of JCML and IMo7 using the criteria described above. Table 2 shows the clinical and laboratory findings in the patients who were reclassified as JCML, IMo7 syndrome, and the remaining patients with CMML who did not have features of these diagnoses. The majority of the patients in these three groups could be readily distinguished from each other and the remaining patients with MDS. The 19 patients with JCML were predominantly male (16 cases) and 11 had a rash at diagnosis; a further child developed the typical rash later in the disease.
There were no consistent cytogenetic abnormalities, although two had trisomy 8. Only two patients classed as JCML produced diagnostic problems; case 20 with RA, gross dyserythropoesis, thrombocytopenia, and an elevated HbF developed a typical rash, and proved resistant to all chemotherapy, whereas case 21 was typical in every way, except that he lacked an absolute monocytosis at the time of diagnosis.
The patients with IMo7 were also predominantly male with morphologic features of RAEB or CMML. Cases 35 and 36 were lost to follow-up. Case 47 had monosomy 7 and has been classified in the group of other CMML because he was 9 years old at diagnosis. However, as symptoms of recurrent infection had been present for many years, he probably represents a case of undiagnosed IMo7. A summary of the expanded classification with numbers of all the other subtypes of MDS is shown in Table 3 .
Trunsfiwmation to AML. Table 3 also shows details of transformation to AML; no patient transformed to lymphoblastic leukemia. Transformation may have been underestimated within this series. Many patients had supportive treatment only and few subsequent investigations, but it was seen in 14 of the 60 patients for whom there was sufficient followup information. Transformation occurred almost exclusively in patients with RA, RAEB, RAEBT, or IMo7, almost half of whom developed AML. The rapid clinical deterioration in most cases of JCML was associated with increasing requirement for blood products and debilitation, rather than development of frank AML.
Response to treatment. The patients were followed over a period of 23 years, during which time, treatment was extremely variable, ranging from supportive care only to bone marrow transplantation using a matched unrelated donor (MUD). Table 4 shows brief details of the treatments received according to the modified FAB classification. Thirty-one patients received supportive treatment only or oral treatment with mercaptopurine and steroids; eight of these are alive between 3.5 and 12.5 years from diagnosis, but the two patients with RA are still transfusion-dependent. Three patients were treated in infancy with splenectomy alone for hypersplenism with increasing spleen size, and are no longer transfusion-dependent more than 4, 18, and 22 years from diagnosis.
Nineteen children received intensive chemotherapy given for AML" (all except one before transformation), augmented in three cases by autologous bone marrow transplant (ABMT) with unpurged, but morphologically and cytogenetically normal bone marrow, after a preparative regime of busulphan and cyclophosphamide. Seven achieved a clinical and cytogenetic remission. Three of these subsequently relapsed, but the other four remain in first remission, three after chemotherapy alone and one after additional ABMT: a fifth is alive in second remission after an isolated testicular relapse. Twelve patients received an allogeneic BMT, eight from a histocompatible sibling and four from other donors: five of the 12 survive. None of the four children with JCML who received intensive chemotherapy achieved a remission. Survival. Three of the patients have been lost to followup. The overall 5-year survival rate for the remaining 65 was 31.9% (95% CI, 21.7% to 44.1%), but there was considerable variation between subgroups. Analysis of survival according to FAB type showed a significant difference ( P = .013), but our revised classification produces a more even distribution of patients and is more highly significant (Fig 2) P = . 00009. The only survivor with JCML is one of the four who had a BMT. Six of 10 children with other CMML survive. The one patient with RARS, omitted from these graphs, died after BMT from a matched unrelated donor. Two of the three patients with eosinophilia (also omitted from the graphs) are alive, one on interferon and the other after a course of hydroxyurea, at 4.9 and 5.9 years, respectively, whereas the third died at 7 months from diagnosis.
Prognostic factors. The factors shown to influence prognosis in univariate analysis are listed in Table 5 . When all the patients were included in the analysis, sex and age were PASSMORE 
01).
A low platelet count and elevated HbF at diagnosis were both associated with a poor prognosis. The children classed by us as having JCML had a worse survival rate than those with IMo7 (chi-squared = 8.28 with 1 df, P = ,004). When patients from all revised FAB types were considered together, again those with JCML had significantly shorter survivals than those with IMo7 or CMML (chi-squared = 15.52
with l df, P = .00008).
The proportion of blasts in blood or marrow was not significant nor was the presence of ALIP in the bone marrow trephine, but the number of cases studied was small.
Stratification by cytogenetic complexity score showed a significant difference between a score of one and two and all the patients with complex abnormalities have died.
The Bournemouth score' (based on diagnostic values for hemoglobin, neutrophil count, platelet count, and percentage bone marrow blasts), could be assigned to 62 of the 65 patients with follow-up data. Seventeen of the patients had a score of two and 28 scored three, with no survival difference between these two groups. As this constituted over twothirds of the patients, the score proved a poor method of discrimination. The more recently described modified Bournemouth system4 adds cytogenetic score, other cytopenias, and ALIP, but in our series, these latter two variables did not have significant prognostic value and so the system was not helpful.
In view of the above findings, we developed a pediatric scoring system (HbF-Platelets-Cytogenetics [WC]), based on objective criteria that could be measured at diagnosis. Each of the following factors scored one point if present at diagnosis: platelets 540 X lo9& cytogenetic complexity score of two, and HbF more than 10%. Those patients who scored two or more were compared with those scoring 0 or one, with the highly significant result shown in Fig 3. The FPC score, as seen in Table 5 significant discrimination than morphologic subtypes or adult scoring systems. The score retained prognostic significance after the exclusion of patients with JCML and RAEBT ( P = .0002).
DISCUSSION
Both myelodysplasia and myeloproliferative diseases are uncommon in childhood and, perhaps because small series of patients are the norm, the nomenclature has remained confusing. The traditional hematologic separation of myelodysplasia and myeloproliferative disorders is one that was not made in early pediatric reference^.^^^^^ There is particular confusion over the term Juvenile Chronic Myeloid Leukemia, which was coined originally to distinguish it from Ph' positive CGL and is somewhat of a misnomer because these patients have the blood and bone marrow appearances of myelodysplasia, usually that of CMML.' Other nonleukemic myeloproliferative diseases are exceptionally rare,I6 and we encountered no cases of polycythemia rubra vera or essential thrombocythemia.
The absolute incidence of MDS in childhood is unknown and a true estimate must await prospective, population-based studies. The reported incidence rates, hitherto based on relatively small populations, have suggested that MDS comprises 1.1% to 8.7% of hematologic malignancies in childh o~d .~.~~ This series of children comprises the largest group of pediatric MDS reported to date, and has the advantage that cytogenetic analysis has been performed in most cases. We have identified a number of problems with definition and classification, using the methods designed for adult MDS, and have attempted to resolve these by modification of the FAB system and by the use of a pediatric prognostic score.
Nineteen of the patients had other clinical abnormalities Total with follow-up = 65.
t Heterogeneity or trend (T).
or a family history of MDS. There are a number of wellrecognized genetic disorders, which predispose to letkmkt and MDS, and several of these were represented, notably Shwachman's syndrome,25 familial platelet storage pool defects," and NF. Patients with NF appear to have a distinct risk of JCML, and probably TMo7." Both IMo7 and JCML were far more common in boys as has been noted previously.x,2x However, none of the 12 children classified as IMo7 had an affected family member as described in other reports.?"."" Three of our patients had constitutional chromosomal abnormalities, although it is unclear whether these played a part in the evolution of the disease process.
It was possible to assign FAB classification to all patients in the study, except the three children with eosinophilia. The major limitation of the system was the finding that a large number of children had CMML (reflecting the high frequency of monocytosis in children with these disorders), and that their prognoses and responses to treatment were very variable; some dying within months and others experiencing long-term survival with minimal treatment. The patients reclassified as JCML tended to be older, to have an extremely poor prognosis, and were unresponsive to any form of chemotherapy. Our findings confirm a previous report8 from the Hopital St Louis, which preceded the acceptance of the FAB system, and described the clinical variability and outcome in a group of children with morphologic CMML. They found, like us, that older children with CMML had a worse prognosis; however, we were unable to show any relation between blast count and prognosis.
The distinction between JCML and IMo7, our other additional subgroup, is not always straightforward and difficulties in discriminating between the two disorders have been emphasized previously.3" In fact, our patients could be assigned fairly easily and this distinction was a helpful one, with a significant difference in outcome between the two groups. Monosomy 7 is a common finding in both MDS and AML, and in the latter is associated with a poor response to therapy." It was only children we classed as having IMo7 syndrome who responded to intensive chemotherapy.
The remainder of the children with CMML who were not classed as JCML or IMo7 formed a heterogenous group. Several of these children have had stable disease for many years with minimal treatment or splenectomy only, although morphologic abnormalities persist. There are other, similar cases in the literature.3'. 33 The other FAB types of MDS were all represented in our series, although only one child had RARS, and posed no specific difficulties in classification.
The relative frequency of the various subtypes of MDS in children is unknown. Pooled data from the 1987 MIC workshop'X suggest that in adults RA, RARS, and RAEB each constitute around a quarter of cases, although RA is possibly slightly more common. The dominance of CMML in our cases may reflect referral bias, because this subtype has been in a minority in some recent ~e r i e s .~~' However, it is also possible that predominance in some series of patients with RAEB and RAEBT may reflect the bias of a leukemia referral pattern because careful examination of children referred with suspected AML may show some to have features of MDS; as many as 17% of cases in one ~eries.."~ It seems likely that the more indolent forms of RA and RARS may b e -t t W a g i -b e e e a s e they might not necessarily be referred or may be diagnosed as congenital dyserythropoeitic or sideroblastic anemias.
The risk of transformation to AML in adults with MDS is reported as 15% to 64%.? Although probably underestimated, the development of AML in our series (25%) is in keeping with this range.
Cytogenetic analysis of the bone marrow proved invaluable in assessment and had been performed in 63 of our patients. As in adult patients with MDS, the most common chromosome abnormalities involved chromosomes S, 7, and 8. Two patients with eosinophilia had translocations involving Sq31-33.20, 21 The genes encoding interleukin (IL)-3, IL-4, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) form a cluster in this region on chromosome S, and there is now good evidence that IL-S is the major cytokine involved in the production of specific eosinophilia.35 It is possible that in these two cases, eosinophil overproduction may be the result of inappropriate gene activation caused by the translocations. There is evidence in adults that the chromosomal changes in MDS are not the initiating pathogenic event, especially as many appear late in the clinical course." The fact that increased cytogenetic complexity was associated with shorter survival probably reflects the expansion of a genetically unstable clone in these cases.
Only 7 of 19 children had some response to intensive chemotherapy of the type used in AML. It appears that children with MDS, like adults>.8,7",34 respond poorly to intensive chemotherapy or succumb to infection during prolonged periods of marrow failure.
These problems may be related to paucity of normal marrow precursors or expression of multidrug resistance, which has been reported in 40% of cases of de novo MDS in adults." Bone marrow transplantation appears to be the most effective form of treatment for MDS in c h i l d h~o d~"~~ and five of our eight patients who had BMT from a histocompatible sibling survive. The optimum timing, the type of preparative regimen, and the role of pretransplant chemotherapy remain to be defined. The role of BMT from a matched unrelated donor'" is, as yet, unclear but will become apparent in the next few years.
With the exception of one of the children, a boy with eosinophilic MDS who received a-interferon that resulted in some irnpro~ement,'.~' no patients received other growth factors or cytokine therapy. There is clearly a need for systematic evaluation of this type of therapy in pediatric, as in adult myelodysplasia.
The examination of prognostic factors in this group of patients, seen over a long period of time and given a variety of treatments, must clearly be interpreted with extreme caution. It was undertaken to act as a base for future prospective surveys and to provide some guidance in identifying a very high-risk group of patients who might, for example, benefit from early consideration of BMT from a matched unrelated donor. Conversely, intensive treatment may not be appropriate in patients with no unfavorable prognostic factors, particularly young children with CMML.
The assignment of an FAB type was of some value, but our modification of this was more useful. There was no evidence that a dominance of blasts in either the blood or the bone marrow had a significant effect on survival, and sex and age, other than in the context of CMML, were of no prognostic significance. A number of scoring systems have been described to predict prognosis in adult MDS. The Bournemouth scoring had poor discriminatory power, and we were unable to use the Dusseldorf system3 because one of the components, lactate dehydrogenase (LDH), was not measured in our patients.
Our simple pediatric FPC score based on HbF, the diagnostic platelet count, and cytogenetic score (a straightforward cytogenetic complexity score that does not need to be modified according to the chromosome involved as in the modified Bournemouth system) is completely objective and does not depend on precise assignation of the FAB or modified FAB type. It provided a high level of discrimination between groups, and would clearly identify most patients at risk of early death.
In conclusion, we have shown that a large proportion of children with MDS have associated abnormalities, a finding that must have implications for investigations of pathogenesis. The FAB classification of MDS is of limited value in pediatric myelodysplasia, though with some modifications to admit clinical and cytogenetic information and to incorporate eosinophilic cases, it appears to work well. We have devised a simple scoring system that appears to discriminate between risk groups in pediatric patients-the adult scoring systems did not. Both classification and scoring systems need to be assessed prospectively on large numbers of patients. Population-based studies are needed to determine the true incidence of pediatric MDS and the proportion of the various subtypes. Such studies are now being undertaken.
